Literature DB >> 16562713

Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.

Y Hu1, A R Coates, D A Mitchison.   

Abstract

SETTING: Pyrazinamide (PZA) is an effective sterilising drug in tuberculosis, but its mode of action is controversial.
OBJECTIVE: To test the bactericidal activity of 1.56-100 microg/ml PZA in Hu/Coates models of dormant and rifampicin (RMP) tolerant Mycobacterium tuberculosis.
METHODS: In model 1, bactericidal activity was tested in pH 5.5 medium against 4-day, 30-day or 100-day static, hypoxic cultures. In models 2 and 3, 100 microg/ml RMP was added to a 100-day culture and PZA was added either during incubation with RMP in model 3, or after resuspension in RMP-free medium in model 2.
RESULTS: Model 1: cfu counts on the 100-day and 30-day cultures fell by a maximum of about 1.6 log cfu/ml with increasing culture age, PZA concentration and incubation period, while counts on the 4-day culture showed little change. Model 2: cfu counts at the end of 7 days of recovery showed little bactericidal activity. Model 3: viable bacilli were almost completely eliminated. Bactericidal activity in these models increased with decreasing metabolic bactericidal activity, as measured by the uptake of [3H] uridine into bacterial RNA.
CONCLUSION: PZA differs from other anti-tuberculosis drugs in showing greater bactericidal activity the slower the bacillary metabolic activity, hence its great value as a sterilising drug, likely to remain as an effective companion drug with newer sterilising drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16562713

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  31 in total

1.  Activity of pyrazinamide in the guinea pig model of tuberculosis.

Authors:  Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2010-12       Impact factor: 5.191

2.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

3.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Authors:  Ping Lu; Anna C Haagsma; Hoang Pham; Janneke J Maaskant; Selena Mol; Holger Lill; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 5.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

Review 6.  New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Authors:  Santiago Caño-Muñiz; Richard Anthony; Stefan Niemann; Jan-Willem C Alffenaar
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

7.  Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro.

Authors:  E D Pieterman; M J Sarink; C Sala; S T Cole; J E M de Steenwinkel; H I Bax
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 8.  The chemotherapy of tuberculosis: past, present and future.

Authors:  D Mitchison; G Davies
Journal:  Int J Tuberc Lung Dis       Date:  2012-06       Impact factor: 2.373

Review 9.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

10.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.